Insider Buying: Humacyte, Inc. (NASDAQ:HUMA) Insider Acquires $11,625.00 in Stock

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) insider Shamik J. Parikh bought 7,500 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was acquired at an average cost of $1.55 per share, for a total transaction of $11,625.00. Following the purchase, the insider now owns 7,500 shares in the company, valued at approximately $11,625. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Humacyte Trading Up 8.4 %

Shares of NASDAQ HUMA traded up $0.13 during midday trading on Friday, reaching $1.68. The company's stock had a trading volume of 3,081,887 shares, compared to its average volume of 3,568,026. The company has a market cap of $260.60 million, a price-to-earnings ratio of -1.25 and a beta of 1.62. Humacyte, Inc. has a one year low of $1.15 and a one year high of $9.97. The company has a 50 day moving average price of $2.61 and a 200 day moving average price of $4.05.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.07. The firm had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million. Research analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Humacyte

Hedge funds and other institutional investors have recently made changes to their positions in the company. Endowment Wealth Management Inc. boosted its position in Humacyte by 3.6% during the fourth quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company's stock worth $526,000 after purchasing an additional 3,590 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Humacyte by 18.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company's stock valued at $138,000 after purchasing an additional 4,327 shares in the last quarter. Beacon Pointe Advisors LLC lifted its holdings in shares of Humacyte by 33.3% during the 4th quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company's stock worth $101,000 after acquiring an additional 5,000 shares during the period. Rhumbline Advisers lifted its stake in Humacyte by 4.6% during the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company's stock worth $578,000 after purchasing an additional 5,005 shares during the period. Finally, Teacher Retirement System of Texas grew its stake in shares of Humacyte by 25.3% in the 4th quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company's stock valued at $132,000 after purchasing an additional 5,293 shares during the period. 44.71% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. D. Boral Capital restated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a report on Wednesday, March 26th. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th. Finally, Benchmark reissued a "buy" rating on shares of Humacyte in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Humacyte has an average rating of "Buy" and a consensus target price of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.